News & Events


27th June 2017 - QS Pharma receives approval from European Medicines Agency for commercial manufacture QS Pharma, a Quotient Clinical business, is now approved to manufacture medicinal products for the US, Europe and Japan QS Pharma, the Contract Development and Manufacturing Organisation (CDMO), which was acquired by Quotient Clinical (“Quotient”) in February 2017, today announced it has received approval from the European Medicines Agency (EMA) to manufacture certain medicinal products for commercial use in Europe.Read More



30th May 2017 - Quotient Clinical appoints Azhar Kalim as Chief Commercial Officer Appointment supports Quotient’s strategy to further develop its global commercial footprint following two recent US acquisitions Quotient Clinical (“Quotient”), the drug development services provider, today announced the appointment of Azhar Kalim as Chief Commercial Officer (CCO). Azhar will lead the enhanced commercial team in a new role, with a focus on supporting Quotient’s strategy to further develop its global commercial footprint following two recent US acquisitions.Read More



14th Feb 2017 - Quotient Clinical announces second US acquisition: QS Pharma Quotient Clinical ("Quotient"), the early phase drug develoment services provider, today announces that it has acquired QS Pharma, the contract development and manufacturing organisation (CDMO), based near Philadelphia, US, from Charles River Laboratories International, Inc. Read More